These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 30001324)

  • 1. Modelling how responsiveness to interferon improves interferon-free treatment of hepatitis C virus infection.
    Venugopal V; Padmanabhan P; Raja R; Dixit NM
    PLoS Comput Biol; 2018 Jul; 14(7):e1006335. PubMed ID: 30001324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment.
    Muñoz de Rueda P; Fuentes Rodríguez JM; Quiles Pérez R; Gila Medina A; Martín Álvarez AB; Casado Ruíz J; Ruíz Extremera A; Salmerón J
    World J Gastroenterol; 2017 Jul; 23(25):4538-4547. PubMed ID: 28740342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
    Guedj J; Neumann AU
    J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era.
    Raja R; Baral S; Dixit NM
    Immunol Rev; 2018 Sep; 285(1):55-71. PubMed ID: 30129199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report.
    Aldunate F; Echeverría N; Chiodi D; López P; Sánchez-Cicerón A; Soñora M; Cristina J; Moratorio G; Hernández N; Moreno P
    BMC Infect Dis; 2021 Apr; 21(1):387. PubMed ID: 33902462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of genetic variants of the 5' noncoding region of hepatitis C virus occurs only in patients responding to interferon alpha therapy.
    Lu M; Wiese M; Roggendorf M
    J Med Virol; 1999 Oct; 59(2):146-53. PubMed ID: 10459148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-interferon-α neutralizing antibody induced telaprevir resistance under the interferon-α plus telaprevir treatment in vitro.
    Kuga C; Enomoto H; Aizawa N; Takashima T; Ikeda N; Ishii A; Sakai Y; Iwata Y; Tanaka H; Saito M; Iijma H; Nishiguchi S
    Biochem Biophys Res Commun; 2014 Nov; 454(3):453-8. PubMed ID: 25450683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?
    Chatterjee A; Guedj J; Perelson AS
    Antivir Ther; 2012; 17(6 Pt B):1171-82. PubMed ID: 23186606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The hepatitis C revolution part 1: antiviral treatment options.
    Thiagarajan P; Ryder SD
    Curr Opin Infect Dis; 2015 Dec; 28(6):563-71. PubMed ID: 26524328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations.
    Pawlotsky JM; Germanidis G; Neumann AU; Pellerin M; Frainais PO; Dhumeaux D
    J Virol; 1998 Apr; 72(4):2795-805. PubMed ID: 9525599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral resistance and direct-acting antiviral agents for HCV.
    Aloia AL; Locarnini S; Beard MR
    Antivir Ther; 2012; 17(6 Pt B):1147-62. PubMed ID: 23188771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of alpha interferon-induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance.
    Serre SB; Krarup HB; Bukh J; Gottwein JM
    J Virol; 2013 Dec; 87(23):12776-93. PubMed ID: 24049176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro.
    Castet V; Fournier C; Soulier A; Brillet R; Coste J; Larrey D; Dhumeaux D; Maurel P; Pawlotsky JM
    J Virol; 2002 Aug; 76(16):8189-99. PubMed ID: 12134024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
    Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
    J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients.
    Kieffer TL; Sarrazin C; Miller JS; Welker MW; Forestier N; Reesink HW; Kwong AD; Zeuzem S
    Hepatology; 2007 Sep; 46(3):631-9. PubMed ID: 17680654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of antiviral effect of type I, II, and III interferons on direct-acting antiviral-resistant hepatitis C virus.
    Hamana A; Takahashi Y; Uchida T; Nishikawa M; Imamura M; Chayama K; Takakura Y
    Antiviral Res; 2017 Oct; 146():130-138. PubMed ID: 28864074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C.
    Welch NM; Jensen DM
    Liver Int; 2015 Jan; 35 Suppl 1():11-7. PubMed ID: 25529082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
    Bailly F; Pradat P; Virlogeux V; Zoulim F
    Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.
    Nishibatake Kinoshita M; Minami T; Tateishi R; Wake T; Nakagomi R; Fujiwara N; Sato M; Uchino K; Enooku K; Nakagawa H; Asaoka Y; Shiina S; Koike K
    J Hepatol; 2019 Jan; 70(1):78-86. PubMed ID: 30336183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of chronic HCV genotype 1 coinfection.
    Boesecke C; Rockstroh JK
    Curr HIV/AIDS Rep; 2015 Sep; 12(3):326-35. PubMed ID: 26228050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.